Quick Answer
Caris Life Sciences, Inc. reported Operating Income of $45.11 million for fiscal year 2025.
Caris Life Sciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $45.11M | +117.5% |
| 2024 | -$257.12M | +19.5% |
| 2023 | -$319.55M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $32.64M | +153.7% | +281.5% |
| June 30, 2025 | -$17.99M | +73.2% | +70.4% |
| September 30, 2024 | -$60.84M | — | +9.2% |
| June 30, 2024 | -$67.01M | — | — |
- Caris Life Sciences, Inc. showed an increase of +117.5% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Caris Life Sciences, Inc.’s operating income has grown by 114.1% (from -$319.55 million to $45.11 million).
- The most recent figure is from Caris Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: